Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
31-45 of 4175 results
Onxeo’s liver cancer drug Livatag fails in phase 3 trial
By PBR Staff Writer
French biotechnology company Onxeo has announced that its liver cancer drug Livatag (doxorubicine Transdrug) failed to meet the primary endpoint in a phase 3 trial in adult patients with unresectable hepatocellular carcinoma (HCC).
Contract Research & Services > Clinical Trials > News
AstraZeneca’s Imfinzi lung cancer drug shows significant effect in PACIFIC trial
AstraZeneca and MedImmune have presented the full PFS data from a planned interim analysis of the phase III PACIFIC trial.
Contract Research & Services > Clinical Trials > News
IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical results
IRX Therapeutics has presented results from a Phase 2a clinical trial of IRX-2, the company’s lead drug candidate, in head and neck squamous cell carcinoma (SCCHN) at the European Society for Medical Oncology (ESMO) Annual Congress 2017.
Contract Research & Services > Clinical Trials > News
Teva’s migraine drug fremanezumab succeeds in phase 3 studies
By PBR Staff Writer
Teva Pharmaceutical has reported that its migraine drug fremanezumab had succeeded in its phase 3 HALO studies by meeting all its 25 primary and secondary endpoints.
Contract Research & Services > Clinical Trials > News
Kura Oncology reports positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer
Kura Oncology has announced positive topline results from a phase 2 trial for its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC).
Contract Research & Services > Clinical Trials > News
AstraZeneca’s COPD drug Duaklir meets primary endpoints in phase III Amplify trial
By PBR Staff Writer
AstraZeneca’s Duaklir (aclidinium bromide/formoterol 400µg/12µg twice-daily) has met its primary endpoints in the Phase III Amplify trial of patients with chronic obstructive pulmonary disease (COPD).
Contract Research & Services > Clinical Trials > News
Roche’s lung cancer drug Alecensa shows significant effect in global phase III study
By PBR Staff Writer
Roche’s lung cancer drug Alecensa (alectinib) has showed significant effect in the phase III ALUR study.
Contract Research & Services > Clinical Trials > News
Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly
Midatech Pharma has announced the submission of a clinical trial application (CTA) for a first in human study of its MTD201 programme in carcinoid cancer and acromegaly.
Contract Research & Services > Clinical Trials > News
Novartis multiple sclerosis drug Gilenya shows siginificant effect in phase III trial
By PBR Staff Writer
Novartis’ multiple sclerosis (MS) drug Gilenya (fingolimod) has demonstrated significant effect in the phase III Paradigms study.
Contract Research & Services > Clinical Trials > News
Otonomy’s Otividex fails to meet primary endpoint in phase 3 trial for Ménière's Disease
Otonomy has announced results for its AVERTS-1 Phase 3 clinical trial of Otividex in patients with Ménière’s disease.
Contract Research & Services > Clinical Trials > News
Merck cholesterol drug reduces heart risk by 9% in study
By PBR Staff Writer
Merck’s cardiovascular treatment anacetrapib has reduced the risk of major coronary events in the REVEAL study.
Contract Research & Services > Clinical Trials > News
Apellis’ APL-2 meets primary endpoint in phase 2 study in patients with geographic atrophy
Apellis Pharmaceuticals’ complement C3 inhibitor, APL-2, met its primary endpoint in phase 2 clinical trial conducted on patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD).
Contract Research & Services > Clinical Trials > News
Cancer Research UK launches clinical trial to test new cancer drug
Cancer Research UK has launched a clinical study to evaluate a new cancer drug in patients with advanced solid tumours in four centres across the UK through its Centre for Drug Development.
Contract Research & Services > Clinical Trials > News
Ultragenyx’ Ace-ER fails in phase 3 GNE Myopathy trial
Ultragenyx Pharmaceutical’s phase 3 study evaluating aceneuramic acid extended release (Ace-ER) in patients with GNE Myopathy (GNEM) failed to meet primary endpoint of showing a statistically significant difference in the upper extremity muscle strength composite score compared to placebo.
Contract Research & Services > Clinical Trials > News
ViraCyte announces positive phase 2 trial results
ViraCyte has announced publication of positive data from a Phase 2 clinical trial evaluating its most advanced T-cell immunotherapy product, Viralym-M.
Contract Research & Services > Clinical Trials > News
31-45 of 4175 results